SCHEMBL24252646

SCHEMBL24252646

COc1cc(C)c(B(O)O)cc1-c1ccc2c(N)nnc(C)c2c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DHFR P00374 5/20 0.36
MAP4K4 O95819 1/20 0.34
FYN P06241 6/20 0.34
CHEK2 O96017 2/20 0.33
ALDH1A1 P00352 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
KIT P10721 1/20 0.32
PDE10A Q9Y233 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
TGFBR1 P36897 1/20 0.31
ACVR1 Q04771 1/20 0.31
LIMK1 P53667 1/20 0.31
PLG P00747 1/20 0.31
PLAU P00749 1/20 0.31
PLAT P00750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25259596 0.94 DHFR (0.33) DHFRMAP4K4FYNCHEK2
Formic Acid SCHEMBL30453086 0.94 DHFR (0.33) DHFRMAP4K4FYNCHEK2
SCHEMBL26771073 0.93 DHFR (0.34) DHFRMAP4K4FYNCHEK2ALDH1A1
SCHEMBL24252368 0.88 PLAU (0.36) DHFRMAP4K4FYNCHEK2PDE10A
SCHEMBL24252645 0.88 FYN (0.34) DHFRMAP4K4FYNCHEK2TDP1
SCHEMBL30451530 0.88 FYN (0.34) DHFRMAP4K4FYNCHEK2TDP1
SCHEMBL30451987 0.88 PLAU (0.36) DHFRMAP4K4FYNCHEK2PDE10A
SCHEMBL25259595 0.87 FYN (0.32) DHFRMAP4K4FYNCHEK2
SCHEMBL24252348 0.85 PGR (0.36) DHFRALDH1A1TDP1MEN1KMT2A
SCHEMBL24252696 0.85 DHFR (0.34) DHFRMAP4K4FYNCHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 DHFR 1380/4885MAP4K4 2769/4885FYN 1558/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 DHFR 1380/4885MAP4K4 2769/4885FYN 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.